Paradigm Biocapital Advisors LP: APOGEE THERAPEUTICS INC (APGE): Quarterly 13F Position History
As of Q2 2026, Paradigm Biocapital Advisors LP reported 1,576,385 shares of APOGEE THERAPEUTICS INC (APGE), worth $209.2M and representing 3.9% of its 13F equity book. Quarter-over-quarter share count change: + 228,142 (+16.9%) . The position first appeared in Q1 2024 and has been disclosed across 10 13F-HR filings in Pactolio's tracked window.
- 1,576,385Shares Held (Latest Filing)
- $209.2MReported Market Value (Latest Filing)
- 3.9%Portfolio Weight (% of 13F Equity Book)
- +228,142Quarter-over-Quarter Share Change
- +$95.8MQuarter-over-Quarter Value Change
- 1,576,385Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 10 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 1,576,385 | +228,142 | +16.9% | $209.2M | 3.9% | $132.7 |
| Q1 2026 | 1,348,243 | +225,000 | +20.0% | $113.5M | 2.3% | $84.2 |
| Q4 2025 | 1,123,243 | 398,514 | -26.2% | $84.8M | 2.3% | $75.5 |
| Q3 2025 | 1,521,757 | +563,127 | +58.7% | $60.5M | 1.8% | $39.7 |
| Q2 2025 | 958,630 | 3,077 | -0.3% | $41.6M | 1.8% | $43.4 |
| Q1 2025 | 961,707 | 322,059 | -25.1% | $35.9M | 1.7% | $37.4 |
| Q4 2024 | 1,283,766 | +581,949 | +82.9% | $58.2M | 2.0% | $45.3 |
| Q3 2024 | 701,817 | +371,817 | +112.7% | $41.2M | 1.4% | $58.7 |
| Q2 2024 | 330,000 | 0 | – | $13.0M | 0.5% | $39.4 |
| Q1 2024 | 330,000 | – | – | $21.9M | 0.8% | $66.5 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Paradigm Biocapital Advisors LP first disclose a APGE position in 13F-HR filings?
Paradigm Biocapital Advisors LP first reported APOGEE THERAPEUTICS INC (APGE) on its 13F-HR filing for the period ending 2024-03-31 (Q1 2024). The position has appeared on 10 reported quarters within Pactolio's tracked window.
What was Paradigm Biocapital Advisors LP's most recent quarter-over-quarter share-count change in APGE?
Between Q1 2026 and Q2 2026, Paradigm Biocapital Advisors LP added 228,142 shares of APGE (+16.9%), bringing the total reported position to 1,576,385 shares at a market value of $209.2M.
Does the implied price-per-share represent Paradigm Biocapital Advisors LP's cost basis in APGE?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.